Axsome's depression drug, Auvelity, is driving the top line while Sunosi diversifies its business. The recent FDA nod for Symbravo also bodes well.

Arizona State Retirement System lifted its holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM – Free Report) by 1.8% in the ...

It has two commercial products, Auvelity and Sunosi, and several products in development, including AXS-05 and AXS-07. On March 6, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on the ...

Shares in Axsome Therapeutics have rocketed on FDA approval of its depression therapy Auvelity (formerly AXS-05) – a year after its approval was held up by the regulator. The FDA has cleared ...

Axsome Therapeutics (NASDAQ: AXSM) recently received a number of ratings updates from brokerages and research firms: 3/6/2025 – Axsome Therapeutics had its “buy” rating reaffirmed by analysts at HC ...

AXSM stock rises 20% as it settles Auvelity patent litigation with Teva, protecting the drug's exclusivity in the United States at least until Sept. 30, 2038. On Monday, Axsome Therapeutics ...

They suggest other fast-acting antidepressants could offer a competitive challenge to J&J's drug, including Axsome Therapeutics' recently approved Auvelity (bupropion/dextromethorphan), Sage ...

Background: Dextromethorphan (DM), the d-isomer of the codeine analog levorphanol, is an active ingredient present in a variety of cough and cold remedies. Recently, data generated from a study in ...

After hours: March 10 at 6:31:15 p.m. EDT Loading Chart for AXSM ...